For example, inhibitors of HDAC have emerged as promising candidates to treat cognitive decline, and the FDA approved HDAC inhibitor Vorinostat is currently undergoing trials in Alzheimer's disease patients (ClinicalTrials.gov Identifier: NCT03056495). This evidence concerns the gene HDAC9 and Mental deterioration.